Stock Events

Stock Events

Pulmonx 

$2.31
12
+$0.05+2.21% 20:00 Today
+$0.04+1.82%22:10After hours

Statistics

Day High
2.37
Day Low
2.24
52W High
2.89
52W Low
1.13
Volume
336,759
Avg. Volume
587,980
Mkt Cap
99.21M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

4NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.45
-0.38
-0.31
-0.24
Expected EPS
-0.25662
Actual EPS
N/A

Financials

-59.67%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
90.5MRevenue
-54MNet Income

Analyst Ratings

9.50Average Price Target
The highest estimate is 14.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LUNG. It's not an investment recommendation.
Apple
3
AAPL
Microsoft
3
MSFT
Tesla
3
TSLA
Amazon
3
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
B2gold
BTG
Mkt Cap6.79B
BTG International's interventional pulmonology portfolio, including devices for lung volume reduction, competes directly with Pulmonx's Zephyr Valves.
Medtronic
MDT
Mkt Cap116.83B
Medtronic offers a range of respiratory and monitoring solutions that can compete with Pulmonx's diagnostic and therapeutic technologies.
Boston Scientific
BSX
Mkt Cap75.11B
Boston Scientific Corporation provides various interventional pulmonology solutions, including airway stents and devices for lung cancer diagnosis and treatment, competing with Pulmonx's offerings.
Johnson & Johnson
JNJ
Mkt Cap627.42B
Johnson & Johnson, through its Ethicon subsidiary, offers products for thoracic surgery and lung health, potentially competing with Pulmonx's lung function improvement solutions.
Koninklijke Philips N.V.
PHG
Mkt Cap26.67B
Philips offers a wide range of respiratory care solutions, including sleep and respiratory care devices, which can indirectly compete with Pulmonx's products.
Smith & Nephew
SNN
Mkt Cap12.48B
Smith & Nephew, with its advanced surgical devices, can compete in the space of lung and thoracic surgery, offering alternatives to Pulmonx's solutions.
Intuitive Surgical
ISRG
Mkt Cap139.37B
Intuitive Surgical's da Vinci robotic surgical systems are used in thoracic procedures, offering a high-tech alternative to traditional and minimally invasive lung surgeries.

About

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
Show more...
CEO
Glendon E. French
Employees
296
Country
United States
ISIN
US7458481014
WKN
000A2P1AF

Listings

STU
DE
4NI.STU
F
DE
4NI.F
BOATS
BOATS
LUNG.BOATS
MU
DE
4NI.MU

0 Comments

Share your thoughts

FAQ

What is Pulmonx stock price today?▼
The current price of LUNG is $2.31 USD — it has increased by +2.21% in the past 24 hours. Watch Pulmonx stock price performance more closely on the chart.
What is Pulmonx stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Pulmonx stocks are traded under the ticker LUNG.
Is Pulmonx stock price growing?▼
LUNG stock has risen by +0.87% compared to the previous week, the month change is a +65% rise, over the last year Pulmonx has showed a +50.98% increase.
What is Pulmonx market cap?▼
Today Pulmonx has the market capitalization of 99.21M
When is the next Pulmonx earnings date?▼
Pulmonx is going to release the next earnings report on November 04, 2026.
What were Pulmonx earnings last quarter?▼
LUNG earnings for the last quarter are -0.24 USD per share, whereas the estimation was -0.28 USD resulting in a +14.29% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Pulmonx revenue for the last year?▼
Pulmonx revenue for the last year amounts to 90.5M USD.
What is Pulmonx net income for the last year?▼
LUNG net income for the last year is -54M USD.
How many employees does Pulmonx have?▼
As of August 19, 2026, the company has 296 employees.
In which sector is Pulmonx located?▼
Pulmonx operates in the Health & Wellness sector.
When did Pulmonx complete a stock split?▼
Pulmonx has not had any recent stock splits.
Where is Pulmonx headquartered?▼
Pulmonx is headquartered in REDWOOD CITY, United States.